Pfizer

News

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage ulcerative colitis drug etras

News

Patients '29% less likely to be hospitalised with Omicron'

Data from a real-world study South Africa has indicated that the Omicron variant of COVID-19 is 29% less likely to cause hospitalisation

News

Targeting COVID-19 and cancer with immunotherapy advancements

Omicron may evade Pfizer/BioNTech COVID jab, says study

Preliminary study results from South Africa have suggested that antibodies stimulated by Pfizer and BioNTech's Comirnaty are less effective against the new COVID-19 variant Omicron.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR).

News

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

COVID booster shots increase immunity, trial shows

A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body's T-cell immunity against the disease.

News

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Patients '29% less likely to be hospitalised with Omicron'

Omicron may evade Pfizer/BioNTech COVID jab, says study

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6b...

COVID booster shots increase immunity, trial shows

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks